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Abstract
Background: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents.
For effective treatment, local control of the tumor is absolutely critical, because the chances of long term
survival are <10% and might effectively approach zero if a complete surgical resection of the tumor is not
possible. Up to date there is no curative treatment protocol for patients with non-resectable osteosarcomas,
who are excluded from current osteosarcoma trials, e.g. EURAMOS1. Local photon radiotherapy has previously
been used in small series and in an uncontrolled, highly individualized fashion, which, however, documented
that high dose radiotherapy can, in principle, be used to achieve local control. Generally the radiation dose that
is necessary for a curative approach can hardly be achieved with conventional photon radiotherapy in patients
with non-resectable tumors that are usually located near radiosensitive critical organs such as the brain, the
spine or the pelvis. In these cases particle Radiotherapy (proton therapy (PT)/heavy ion therapy (HIT) may offer a
promising new alternative. Moreover, compared with photons, heavy ion beams provide a higher physical
selectivity because of their finite depth coverage in tissue. They achieve a higher relative biological
effectiveness. Phase I/II dose escalation studies of HIT in adults with non-resectable bone and soft tissue
sarcomas have already shown favorable results.
Methods/Design: This is a monocenter, single-arm study for patients ≥ 6 years of age with non-resectable
osteosarcoma. Desired target dose is 60-66 Cobalt Gray Equivalent (Gy E) with 45 Gy PT (proton therapy) and a
carbon ion boost of 15-21 GyE. Weekly fractionation of 5-6 × 3 Gy E is used. PT/HIT will be administered exclusively
at the Ion Radiotherapy Center in Heidelberg. Furthermore, FDG-PET imaging characteristics of non-resectable
osteosarcoma before and after PT/HIT will be investigated prospectively. Systemic disease before and after PT/HIT is
targeted by standard chemotherapy protocols and is not part of this trial.
Discussion: The primary objectives of this trial are the determination of feasibility and toxicity of HIT. Secondary
objectives are tumor response, disease free survival and overall survival. The aim is to improve outcome for
patients with non-resectable osteosarcoma.
Trail Registration: Registration number (ClinicalTrials.gov): NCT01005043
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Osteosarcoma is the most common primary malignant
bone tumor in children and adolescents but also occurs
in adults. The most frequent primary tumor sites are
the distal femur and the proximal tibia, but there are a
significant number of patients with axial primary tumors
or other unfavorable, non-resectable tumor sites (5-
10%). Effective treatment depends on neoadjuvant and
adjuvant chemotherapy to control micrometastatic dis-
ease, and on radical surgical resection to control the pri-
mary tumor. Local control of the tumor is absolutely
critical, because the chances of long term survival are
<10%, if a complete surgical resection of the tumor is
not possible [1,2]. In a minority of patients, the tumor
cannot be completely resected without unacceptable
mutilation. In such patients local radiotherapy has pre-
viously been used. Published small series of such
patients have documented that radiotherapy can achieve
local control [3], although the success rate of this strat-
egy has not been analyzed in systematic trials.
Although the small series of patients with non-resect-
able tumors, who received local radiotherapy but no sur-
gery showed encouraging results, the necessary high
radiation doses cannot be achieved in many patients
with tumors near critical organs such as the brain, the
spinal cord or small bowel. In such cases PT plus HIT
may offer a promising alternative.
Compared with photons, heavy ion particles such as
carbon ions or protons provide a higher physical selec-
tivity because of their finite depth coverage in tissue
and, in the case of heavy ions, achieve a higher relative
biological effectiveness. Phase I/II dose escalation studies
of HIT in adults with non-resectable bone and soft tis-
sue sarcomas showed favorable results [4,5]. Kamada et
al. demonstrated a 3-year overall survival rate of 45% in
a series of 15 patients with non-resectable osteosarcoma
of the pelvis (10 patients) or the spine (5 patients).
These results are clearly superior to most published
3-year survival rates in patients with non-resectable
osteosarcoma of the pelvis and/or spine, who did not
receive radiotherapy [6,7].
Since 1997, HIT is available for the treatment of
patients at the Gesellschaft für Schwerionenforschung
(GSI) in Darmstadt, Germany. Up to now, more than
400 patients with various tumor types were successfully
irradiated at the GSI [8,9]. From November 2009, HIT
and PT will be available at the University of Heidelberg.
In contrast to other centers, the facility at Heidelberg
relies on active beam delivery using the so called raster
scan technique, which offers physical advantages with
better sparing of normal tissue in the entrance channel,
less scattering dose. Furthermore, biological plan optimi-
zation is performed.
This study aims at improving outcome in patients
with non-resectable osteosarcoma
Methods/Design
Study design
The study is designed as a mono center, single arm
phase I/II pilot trial.
Study objectives
The primary objective is to evaluate the feasibility and
toxicity of dose escalation via PT/HIT in patients with
osteosarcoma. Secondary objectives are the evaluation of
tumor response, disease free survival, overall survival
and description of FDG-PET characteristics in patients
with osteosarcoma before and after PT/HIT in order to
evaluate prospectively the association between FDG-PET
and survival respectively time to progression.
Trial organization
The trial has been designed by the study initiators at the
Department of Radiation Oncology and the Department
of Pediatric Oncology, Hematology, Immunology and
Pneumology. The trial is carried out by the Department
of Radiation Oncology and the Department of Pediatric
Oncology, Hematology, Immunology and Pneumology
at the University of Heidelberg.
Coordination
The overall coordination is performed by the Depart-
ment of Radiation Oncology at the University of Heidel-
berg. This department is responsible for the overall trial
management, database management, quality assurance
including monitoring and reporting.
Investigators
The study investigators are experienced radiation oncol-
ogists respectively pediatricians. Patients will be treated
by the physicians of the Department of Radiation
Oncology and the Department of Pediatric Oncology,
Hematology, Immunology and Pneumology.
Ethics, informed consent and safety
The final protocol was approved by the ethics commit-
tee of the University of Heidelberg, Heidelberg, Ger-
many (Nr. S-153/2008). This trial complies with the
Helsinki Declaration in its recent German vision, the
medical Association code of conduct, the principles of
Good Clinical Practice (GCP) and the Federal Data Pro-
tection Act. The study will also be carried out in keep-
ing with local legal and regulatory requirements. It is
subjected to authorization by the “Bundesamt für Strah-
lenschutz”. The medical secrecy and the Federal Data
Protection Act will be followed.
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The following inclusion criteria must be fulfilled:
▪ Histological diagnosis of high grade osteosarcoma
with or without metastases
▪ Non-resectable* tumor of the pelvis, the skull base
or the spine, respectively, incomplete or intralesional
tumor resection - as confirmed after evaluation by two
orthopedic surgeons (respectively neurosurgeons in case
of spine tumors): one local surgeon and one referee sur-
geon of the University of Heidelberg.
▪ Age ≥ 6 years before start of radiotherapy
▪ Adequate performance status (Karnofsky ≥ 60%)
▪ Adequate blood cell production before the start of
PT/HIT in patients with pelvic or spine tumors as
defined by: total white cell count (WBC) ≥ 1,0/nl; neu-
rophils ≥ 200/μl; platelet count ≥ 20/nl
▪ No febrile neutropenia (neutrophils < 200/μl)
▪ Written informed consent of the patient or the legal
guardians
*Non-resectable tumor site means primary tumors
affecting anatomic areas of the human body where a
surgical total resection (R0) of the tumor is not possible
for technical reasons, for example osteosarcoma of the
pelvis, spine or the skull base. In any other cases, surgi-
cal resection is recommended.
Non-resectability has to be confirmed after evaluation
by two orthopedic surgeons (respectively neurosurgeons
in case of spine tumors): one local surgeon and one
referee surgeon of the University of Heidelberg.
In some cases surgery of the tumor might be possible
after PT/HIT. Than we recommend surgical resection of
residual tumor afterwards.
Exclusion criteria
▪ Age < 6 years
▪ Previous radiotherapy of the field that has to be
radiated now
▪ Implanted metal within the planned radiation field,
that leads to significant artefacts within the target
volume
▪ Patients receiving any other investigational agents
during the time of HIT
▪ Performance status (Karnofsky) ≤ 60%)
▪ Pregnancy
▪ No written informed consent of patient or the legal
guardians
Statistical calculations for trial sample size
20 patients ≥ 6 years will be included in the trial. This
number ensures acceptable 95%-confidence intervals for
the description of incidence of toxicities as well as for
the efficacy of the HIT-treatment in this trial. For
response rates of 30% the 95%-confidence interval will
be 17.9-44.6%.
Adverse events
Radiotherapy-related toxicities will be assessed using the
NCI Common Terminology Criteria (CTC). Toxicity
will be evaluated pre-treatment, weekly during radiation
therapy (blood count, electrolytes, chemistry, clinical
examination, patient visits) and at follow-up (1 week, 6
and 19 weeks, 6, 12, 24, 36 48 and 60 months after PT/
HIT). Unacceptable toxicity is defined as unpredictable
or irreversible grade 4 toxicity.
Expectable possible acute toxicities (up to 3 months
post PT/HIT) are
- Depression of hematopoesis
- Mucosa: ulcera, chronic inflammation, colic, diar-
rhoea, bowel stenosis, urinary bladder inflammation,
contracted bladder
- Skin: erythema, epitheliolysis
- CNS: sickness, vomiting, central nerve palsy, ele-
vated intracranial pressure, headach, dizziness
- sceletal system: necrosis, fracture, joint dysfunction,
disturbance of growth
Late effects are rare and defined as symptoms appearing
at least 3 months post irradiation. These could include:
- Bowel stenosis or perforation with need for surgi-
cal intervention
- Chronic bowel inflammation
- CNS: central nerve palsy, cerebral palsy, impaired
vision, defective hearing (very rare)
- Disturbance of growth
- Secondary malignancies: The incidence of second-
ary malignancies is possibly increased by high-LET
radiotherapy like HIT
- arteriosclerosis
- Incontinence (very rare)
- Impotence (very rare)
A rate of acute toxicity (≤ 3 months during respec-
tively after PT/HIT) > grade 3 of ≤ 5% and a rate of late
toxicity (after ≥ 3m o n t h s )>g r a d e3o f≤ 3% will be
regarded as acceptable.
Radiation therapy, process of PT/HIT
All patients with osteosarcoma who meet the above
mentioned criteria will be included. Chemotherapy prior
and after HIT is recommended according to standard
therapy protocols like EURAMOS1 and is not part of
this trial protocol.
PT and HIT will be administered at the Department
of Radiotherapy of Heidelberg University at least one
week after the last chemotherapy cycle, if the inclusion
criteria have been met. HIT will be given mainly on an
outpatient basis on 5-6 days per week but with daily
Blattmann et al. BMC Cancer 2010, 10:96
http://www.biomedcentral.com/1471-2407/10/96
Page 3 of 7clinical examinations by a radiotherapist respectively by
a pediatrician. Necessity of inpatient basis has to be ver-
ified individually for example in case of adverse events
during PT/HIT. Then the treatment will be arranged
and supervised by the Department of Pediatric Oncol-
ogy, Hematology, Immunology and Pneumology of the
Heidelberg University.
No treatment other than PT/HIT may be adminis-
tered during PT/HIT.
After the end of PT/HIT, adjuvant chemotherapy can
be continued within one week according to standard
therapy protocols, e.g. according to EURAMOS 1 trial
arm “poor response” (figure 1).
Technique
Patients will be rigidly immobilized to ensure a high
repositioning accuracy of the tumor region and adjacent
structures for PT/HIT. Set-up deviations larger than > 1
mm in the skull base region and larger than 3 mm in
the spinal and pelvic region will be corrected prior to
each irradiation. If necessary, children will be anesthe-
tized for the procedure.
The planning target volume results from the clinical
target volume plus a safety margin that depends on
tumor site and immobilization technique.
GTV (Gross Tumour Volume) is delineated according
to MRI/CT-Scan/PET-CT.
CTV(Clinical Target Volume) contains the visible
GTV + the subclinical microscopic malignant disease.
The original (pre-chemotherapy, pre-operative) tumour
extension should guide the CTV-delineation. In axial
tumours a clinical safety margin of 2 cm added to the
GTV should be attempted. For extremity sarcomas a
margin of 4-5 cm around the GTV is preferred.
PTV (Planning Target Volume) is delineated in colla-
boration with the radiation-physicist taking into account
organ and patient movement as well as inaccuracies in
beam and patient set-up.
Organs at risk such as rectum, bladder, femoral heads,
central nerves, spinal cord are contoured.
The quality of patient immobilization will be checked
quantitatively daily via digital x-ray equipment. During
HIT, set-up is checked daily with a system based on
orthogonal x-ray devices and set-up deviations >1 mm
Patient´s 
registration 
at least 3 
weeks before 
start of 
HIT/PT 
FDG-
PET, 
optional 
Obligatory diagnostics after
HIT/PT:
FDG-PET  
week 15 + end of therapy
CT/MRI and GK - Tc99 
skeletal scintigraphy 
week 20 + end of therapy
Follow-up 
diagnostics 
6, 12, 24, 
36, 48 and 
60 months 
after HIT/PT 
Neoadjuvant chemotherapy 
according to 
standard therapy protocols 
(e.g. EURAMOS1 ) 
Adjuvant chemotherapy 
according to standard therapy 
protocols  
(e.g. EURAMOS1, HR1 (MAP)) 
Obligatory 
diagnostics 
before HIT/PT:
FDG-PET 
CT/MRT 
GK - Tc99 
Skeletal 
scintigraphy 
week 7-10
Radiotherapy 
(HIT/PT)
(60-66 GyE= 20-40d), 
Figure 1 Chronological course of the therapy trial. HIT/PT will be administered at least one week after the last chemotherapy cycle on 6
days per week. Chemotherapy prior and after HIT/PT is recommended according to standard therapy protocols and is not part of this trial
protocol. After the end of HIT/PT, adjuvant chemotherapy can be continued within one week. Diagnostic investigations have to be done at a
specific date pre and after HIT/PT. FDG-PET characteristics will be evaluated prospectively.
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mity tumors are corrected prior to PT/HIT.
Treatment planning
Treatment planning includes biological plan optimiza-
tion using the local effect model (LEM), which is
included into the treatment planning software. Active
beam delivery using the raster scan system is used to
spare normal tissue surrounding the tumor. Desired tar-
get dose is 60-66 Cobalt Gray Equivalent (Gy E), when-
ever possible. It is applied through 1 - 3 isocentric
treatment portals via proton therapy plus a heavy ion
boost of 15-21 GyE. Dose distributions are calculated
and dose volume histograms (DVH) are generated. A a/
b-ratio of 2 is used for biological plan optimization.
Fractionation is planned to be equivalent to 5 × 2 Gy
PT per week and 5-6×/3 Gy E HIT per week. Dosage to
organs at risk is minimized.
Duration of Therapy
Treatment continues for 20 to 40 days or until one of
the following criteria applies:
▪ Other illness that prevents further administration of
treatment,
▪ Patient or legal guardian decides to withdraw from
the study, or
▪ General or specific changes in the patient’sc o n d i -
tion render the patient unacceptable for further treat-
ment in the judgment of the investigator.
Because the tumors of the patients who are eligible to
be included in this study will not be resectable, the
regression grade following chemotherapy cannot be
determined according to standard criteria. A recent
study showed significant alterations of glucose-uptake in
FDG-PET of osteosarcoma after response to chemother-
apy, which correlated with the histopathologic assess-
ment of response [10-12]. Therefore, in this study FDG-
PET will be used for the prospective evaluation of
tumor response after PT/HIT. If possible, FDG-PET will
be performed before start of neoadjuvant chemotherapy.
FDG-PET has to be performed obligatory no more than
one week before the initiation of PT/HIT (week 10),
after PT/HIT (week 15), at the end of the complete
tumor therapy (week 30) and 6 months after tumor
therapy (figure 1).
Measurement of response
Response and progression will be evaluated in this study
using the new international criteria proposed by the
Response Evaluation Criteria in Solid Tumors (RECIST)
Committee [13]. Changes in the largest diameter (one-
dimensional measurement) of the tumor lesions are
used in the RECIST criteria.
Prospective Evaluation of Fluorodeoxy-D-Glucose Positron
Emission Tomography (PET)
A secondary objective of this study is to describe the
FDG-PET imaging characteristics in patients with osteo-
sarcoma before and after HIT and to determine the
association between FDG-PET and survival respectively
time to progression.
FDG-PET has to be performed obligatory at 4 time
points: one week before start of PT/HIT, after PT/HIT,
at the end of complete tumor therapy and 6 months
after PT/HIT. If possible, FDG-PET has to be performed
initially before start of neoadjuvant therapy.
Results, respectively response criteria will be evaluated
in future.
Time plan for the study
The study will be started in January 2010. Patient
recruitment will be completed when 20 patients are
included which is expected latest in 2015. Patient fol-
low-up will continue for at least 5 years within our cen-
ter, and will continue on a regular written basis (once
yearly). The trial will be completed latest in 2020.
Follow-up
Follow-up visits are obligatory 1 week, 6 and 19 weeks,
as well as 6, 12, 24, 36 48 and 60 months after PT/HIT.
For a detailed plan of follow-up diagnostics see table 1.
Monitoring
Monitoring is performed according to good clinical
practice (GCP) guidelines. The monitoring and the data
management will be performed by the Clinical Trial
center of the Department of Radiation Oncology, Uni-
versity of Heidelberg.
Discussion
Osteosarcoma is the most common bone tumor in chil-
dren. Local control is absolutely critical concerning sur-
vival. Standard therapy protocols consist of surgical
resection of the primary tumor and polychemotherapy.
Until now, there has been no standard therapy protocol
for non-resectable tumors.
For a long time, osteosarcoma was supposed to be a
radioresistant tumor, but published small series of
osteosarcoma patients have shown that radiotherapy
with photons can achieve local control. However, a high
radiation dose has to be applied, that usually cannot be
given in non-resectable (mainly axial) tumors that are
located close to critical organs like the brain, the spine
or the bowels.
Particle therapy, respectively proton and carbon ion
beams, have the advantage of a superior biological dose
distribution that permits radiation with high doses even
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fall-off after the so called “Bragg peak”, which minimizes
effects to normal tissue behind the Bragg peak. Further-
more, the relative biological effectiveness (RBE) of heavy
ion beams within the Bragg peak is higher than that of
photon beams and therefore has the potential advantage
of providing a higher local effect in tumors that, like
sarcomas, show low sensitivity to conventional radiation.
Promising results have been obtained with HIT for a
number of tumors in Japan as well as at the
“Gesellschaft für Schwerionenforschung” (GSI) in Darm-
stadt, Germany. 3 year-local control rates of 73% for
bone and soft tissue sarcomas were reported from the
National Institute of Radiological Sciences in Japan
[4,14]. At the GSI, high local control rates with minimal
toxicity have been achieved for patients with chordomas
and chondrosarcomas of the skull-base as well as ade-
noidcystic tumors [8]. From 2009, HIT will also be
available at the University of Heidelberg. In contrast to
other centres, the facility in Darmstadt (GSI) as well as
the new facility in Heidelberg relies on active beam
delivery using the so called raster scan technique, which
offers physical advantages with better sparing of normal
tissue in the entrance channel as well as less scattering
dose. Moreover, the treatment planning procedure also
includes biological plan optimization [15].
PT plus HIT seems to offer a new promising therapy
option in patients with osteosarcoma little is known
about side effects of HIT in children, but until now there
is no curative alternative for inoperable osteosarcoma.
Therefore, we have designed a phase I/II trial for patients
with non-resectable osteosarcoma respectively patients
who or whose legal guardians refuse local surgical resec-
tion. The purpose is to investigate the safety and toxicity
of dose escalation via HIT as well as its efficacy in order
to improve local control and outcome in these patients.
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